Huang, M.; Wang, W.; Yu, Q.; Zhou, Y.; Wang, Y.; Wang, R.; Li, X.; Zhou, Y.; Zhang, Y.; Tian, R.
A Bioorthogonal TCO–Tetrazine-Based Pretargeted PET/NIRF Platform Enabling High-Contrast Tumor Imaging. Pharmaceuticals 2025, 18, 1874.
https://doi.org/10.3390/ph18121874
AMA Style
Huang M, Wang W, Yu Q, Zhou Y, Wang Y, Wang R, Li X, Zhou Y, Zhang Y, Tian R.
A Bioorthogonal TCO–Tetrazine-Based Pretargeted PET/NIRF Platform Enabling High-Contrast Tumor Imaging. Pharmaceuticals. 2025; 18(12):1874.
https://doi.org/10.3390/ph18121874
Chicago/Turabian Style
Huang, Mingxing, Weichen Wang, Qiao Yu, Yike Zhou, Yingwei Wang, Rang Wang, Xin Li, Yaojia Zhou, Yi Zhang, and Rong Tian.
2025. "A Bioorthogonal TCO–Tetrazine-Based Pretargeted PET/NIRF Platform Enabling High-Contrast Tumor Imaging" Pharmaceuticals 18, no. 12: 1874.
https://doi.org/10.3390/ph18121874
APA Style
Huang, M., Wang, W., Yu, Q., Zhou, Y., Wang, Y., Wang, R., Li, X., Zhou, Y., Zhang, Y., & Tian, R.
(2025). A Bioorthogonal TCO–Tetrazine-Based Pretargeted PET/NIRF Platform Enabling High-Contrast Tumor Imaging. Pharmaceuticals, 18(12), 1874.
https://doi.org/10.3390/ph18121874